Court Dismisses Privacy Claims Against IQVIA in Rose v. IQVIA Holdings Inc.
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
Stocks · News reference
Rothschild & Co Redburn has increased its price target for IQVIA Holdings Inc. from $287 to $299.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
A federal court dismissed privacy-related claims against IQVIA regarding its operation of Drugs.com, citing the plaintiffs' failure to specify their search history.
IQVIA projected that U.S. peak annual sales for products utilizing GENFIT's technology could exceed $1.5 billion by 2033.
Truist has increased its price target for IQVIA Holdings Inc. while maintaining a Buy rating on the stock.
IQVIA Holdings Inc. announced its third-quarter 2026 financial results, reporting revenue of $4.43 billion and adjusted earnings per share of $3.34.
Filed: 2026-10-27 AccNo: 0001628280-26-067406 Size: 424 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits